Stock Quote
GTx, Inc. (GTXI.W) (NASD ADF)
$3.57
10 Nov 2009
-2.99%
$3.68
$3.67
1,300
$3.67
$3.57
$18.75
$3.55
0.84
2,217,354
GTXI.W
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Hyde, Joseph | Chairman of the Board | -- |
| Hanover, Marc | President, Chief Operating Officer, Director | 806,854 |
| Steiner, Mitchell | Vice Chairman of the Board, Chief Executive Officer | 710,967 |
Profile
GTx, Inc., is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle wasting and other medical conditions. As of December 31, 2008, the Company is... Full Description
Company Address
GTx, Inc.
3 N. Dunlap Street, 3rd Floor
Van Vleet Building
Memphis TN 38163
P: +1901.5239700
F: +1901.5239772
3 N. Dunlap Street, 3rd Floor
Van Vleet Building
Memphis TN 38163
P: +1901.5239700
F: +1901.5239772
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Eli Lilly & Co. | $36.81 | +0.22 |
| Merck & Co., Inc. | $36.44 | -0.02 |
| Sanofi-Aventis SA | €51.77 | +1.40 |
| GTXI.W | Industry | |
|---|---|---|
| P/E(TTM) | -- | 12.80 |
| P/S(TTM) | 9.47 | 29.90 |
| ROI(TTM) | -56.14 | 2.35 |
| ROE(TTM) | -144.75 | 3.59 |
| Consensus Recommendation | Hold |
|---|---|
| EPS Est. (Current Period) | -0.17 |
| EPS Est. (Current Year) | -1.32 |
| Total Revenue | $3.82M |
| Net Income | $-11.26M |
| EPS | $-0.31 |
